Table 2.
Pooled risk ratios of lung cancer in individuals exposed to ACEIs stratified by subgroups.
| Subgroups | RR (95% CI) | Q (P -value) | Number of studies | Heterogeneity I2 (P -value) |
| Study design | 0.65 (.72) | |||
| Case-Control | 1.06 (0.82–1.37) | 4 | (0).44 | |
| Cohort | 0.94 (0.81–1.10) | 8 | (85.8%) <.001 | |
| RCT | 1.01 (0.65–1.56) | 1 | (0) 1.00 | |
| Comparator regimen | 3.37 (.19) | |||
| ARB | 1.11 (0.89–1.39) | 4 | (0) .60 | |
| BB/CCB/D | 0.82 (0.64–1.05) | 6 | (88.9%) <.001 | |
| Controls | 0.91 (0.66–1.25) | 3 | (36.9) .21 | |
| Duration of ACEI use | 0.05 (.83) | |||
| ≤5 years | 0.95 (0.75–1.20) | 9 | (76.7%) .001 | |
| >5 – 10 years | 0.98 (0.83–1.15) | 4 | (82.3%) .001 |